Expression of FOXP1 and Colorectal Cancer Prognosis

Smedt, Linde De; Palmans, Sofie; Govaere, Olivier; Moisse, Matthieu; Boeckx, Bram; Hertogh, Gert De; Prenen, Hans; Cutsem, E. Van; Tejpar, Sabine; Tousseyn, Thomas

doi:10.1309/lm7ihv2nji1phmxc

Cited by 19 publications

(20 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In total, 2468 tumor patients from 9 different countries were included in our meta-analysis, and the studies were published from 2004 to 2015. The tumor types contained are as follows: DLBCL 13 14 15 20 24 25 26 27 28 29 , breast cancer 16 30 31 , endometrial cancer 17 , MALT lymphoma 14 32 33 34 , hepatocellular carcinoma 35 , NSCLC 18 , prostate cancer 12 , colorectal cancer 36 and epithelial ovarian cancer 37 . As for the survival outcomes, 22 eligible studies were divided into 31 datasets: 20 for OS, 4 for PFS, 3 for RFS, 2 for DFS, 1 for CSS and 1 for FFS ( Table 1 and Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Second, decreased expression of FOXP1 is an unfavorable factor for solid tumors. As the meta-analysis results were pooled from breast cancer 16 30 31 , endometrial cancer 17 , hepatocellular carcinoma 35 , NSCLC 18 , prostate cancer 12 , colorectal cancer 36 and epithelial ovarian cancer 37 , and combined with further evidence from neuroblastoma 11 , we considered that this finding may be applicable to all solid tumors. Third, FOXP1 protein may function as a tumor promoter in lymphomas and act as a tumor suppressor in solid tumors.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis

Xiao

Zou

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The prognostic value of forkhead box protein P1 (FOXP1) protein expression in tumors remains controversial. Therefore, we conducted a systematic review and meta-analysis, searching the PubMed, Embase and Web of Science databases to identify eligible studies. In total, we analyzed 22 articles that examined 9 tumor types and included 2468 patients. Overall, decreased expression of FOXP1 protein was associated with favorable overall survival (OS) in lymphoma patients (HR = 0.38, 95%CI: 0.30–0.48, p < 0.001). In patients with solid tumors, decreased FOXP1 expression correlated with unfavorable OS (HR = 1.82, 95%CI: 1.18–2.83, p = 0.007). However, when FOXP1 protein expression was nuclear, decreased expression was also associated with favorable OS (HR = 0.53, 95%CI: 0.32–0.86, p = 0.011). Furthermore, decreased FOXP1 expression resulted in the best OS in patients with mucosa-associated lymphoid tissue (MALT) lymphomas (HR = 0.26, 95%CI: 0.11–0.59, p = 0.001), but the worst OS was observed in non-small cell lung cancer (NSCLC) patients (HR = 3.11, 95%CI: 1.87–5.17, p < 0.001). In addition, decreased FOXP1 expression was significantly correlated with an unfavorable relapse-free survival (RFS) in breast cancer patients (HR = 1.93, 95%CI: 1.33–2.80, p = 0.001).

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis

Xiao

Zou

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…22 Of important note, CCR1 also was identified to be regulated by FOXP1 in colon cancer cell lines. 23 As such, we attempted to determine the role of CCR1 in FOXP1 siRNA-induced growth and invasion of lung cancer cells, we transfected A549 and PC9 cells with CCR1 siRNA in addition to FOXP1 siRNA transfection and measured the cancer cell growth and invasion. As shown in Figure 4, knockdown of CCR1 reduced the growth and invasion of lung cancer cells.…”

Section: Chemokine Signaling Pathway Is Involved In Foxp1mediated Tummentioning

confidence: 99%

Knockdown of FOXP1 promotes the development of lung adenocarcinoma

Shu

2018

Cancer Biology & Therapy

View full text Add to dashboard Cite

Lung cancer is one of the most common cancers in the world, which accounts for about 27% of all cancer deaths. However, the mechanisms underlying the pathogenesis of lung cancer cells remain largely elusive. In this study, we examined the role of the Forkhead box protein P1 (FOXP1) in lung cancer development. Our Oncomine analysis shows that FOXP1 is downregulated in lung adenocarcinoma compared with normal lung tissue. Knockdown of FOXP1 promotes the growth and invasion of PC9 and A549 cells by regulating genes of chemokine signaling molecules, including CCR1, ADCY5, GNG7, VAV3, and PLCB1. Simultaneous knockdown of CCR1 and FOXP1 attenuated FOXP1 knockdowninduced increase of lung cancer cell growth. Finally, knockdown of FOXP1 in PC9 cells promotes the tumorigenesis via CCR1 signaling in xenograft mouse model. Taken together, our data suggest that FOXP1 plays important roles in preventing lung adenocarcinoma development via suppressing chemokine signaling pathways. ARTICLE HISTORY

show abstract

“…FOXP1 has been located to chromosome 3p14.1, a chromosomal locus that has been shown to be disrupted in a series of solid tumors [ 25 ]. Many studies have revealed that FOXP1 is aberrantly expressed in several types of cancers and its expression frequently has a significant correlation with aggressive malignant phenotypes of tumors and poor prognosis in patients [ 11 , 12 , 16 , 17 , 18 , 19 , 21 , 26 , 27 ]. Therefore, these findings suggest that FOXP1 indeed plays an important role in solid cancers and led us to investigate the role of FOXP1 in HCC.…”

Section: Discussionmentioning

confidence: 99%

Downregulation of FOXP1 Inhibits Cell Proliferation in Hepatocellular Carcinoma by Inducing G1/S Phase Cell Cycle Arrest

Wang

Sun

Cui

et al. 2016

IJMS

View full text Add to dashboard Cite

Forkhead box P1 (FOXP1) belongs to a family of winged-helix transcription factors that are involved in the processes of cellular proliferation, differentiation, metabolism, and longevity. FOXP1 can affect cell proliferation and migratory ability in hepatocellular carcinoma (HCC) in vitro. However, little is known about the mechanism of FOXP1 in the proliferation of HCC cells. This study aimed to further explore the function of FOXP1 on the proliferation of HCC cells as well as the relevant mechanism involved. Western blot analysis, tumor xenograft models, and flow cytometry analysis were performed to elucidate the function of FOXP1 in the regulation of cell proliferation in human HCC. We observed that silencing FOXP1 significantly suppressed the growth ability of HCC cells both in vitro and in vivo. In addition, knockdown of FOXP1 induced G1/S phase arrest, and the expression of total and phosphorylated Rb (active type) as well as the levels of E2F1 were markedly decreased at 24 h; however, other proteins, including cyclin-dependent kinase (CDK) 4 and 6 and cyclin D1 did not show noticeable changes. In conclusion, downregulation of FOXP1 inhibits cell proliferation in hepatocellular carcinoma by inducing G1/S phase cell cycle arrest, and the decrease in phosphorylated Rb is the main contributor to this G1/S phase arrest.

show abstract

Expression of FOXP1 and Colorectal Cancer Prognosis

Abstract: In our case series, loss of FOXP1 was associated with reduced survival rates in CRC tissue. Also, FOXP1 affects proliferation and inflammatory reaction in colorectal neoplasia.

Cited by 19 publications

References 44 publications

Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis

Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis

Knockdown of FOXP1 promotes the development of lung adenocarcinoma

Downregulation of FOXP1 Inhibits Cell Proliferation in Hepatocellular Carcinoma by Inducing G1/S Phase Cell Cycle Arrest

Contact Info

Product

Resources

About